Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
J Thorac Dis. 2022 Apr;14(4):816-819. doi: 10.21037/jtd-22-98.
J Thorac Dis. 2022.
PMID: 35572898
Free PMC article.
No abstract available.
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.
Baglivo S, Mandarano M, Bellezza G, Minotti V, Bonaiti A, Fischer MJ, Birocchi I, Roila F, Metelli N, Ludovini V, Metro G.
Baglivo S, et al. Among authors: bonaiti a.
Oncol Ther. 2022 Jun;10(1):291-300. doi: 10.1007/s40487-022-00183-7. Epub 2022 Jan 23.
Oncol Ther. 2022.
PMID: 35066813
Free PMC article.
Item in Clipboard
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Metro G, Baglivo S, Metelli N, Bonaiti A, Matocci R, Di Girolamo B, Mandarano M, Colafigli C, Bellezza G, Roila F, Ludovini V.
Metro G, et al. Among authors: bonaiti a.
J Chemother. 2023 Oct;35(6):576-582. doi: 10.1080/1120009X.2022.2157611. Epub 2022 Dec 20.
J Chemother. 2023.
PMID: 36537289
Item in Clipboard
Cite
Cite